Sarms LGD3303 Powder For Bodybuilding CAS:1196133-39-7
Selective Androgen Receptor Modulators (SARMs) are a class of therapeutics designed to mimic the muscle-building effects of anabolic steroids while minimizing androgenic side effects. LGD-3303, developed by Ligand Pharmaceuticals, is a potent, nonsteroidal SARM initially investigated for conditions like muscle wasting and osteoporosis.
Introduction to SARMs and LGD-3303
Selective Androgen Receptor Modulators (SARMs) are a class of therapeutics designed to mimic the muscle-building effects of anabolic steroids while minimizing androgenic side effects. LGD-3303, developed by Ligand Pharmaceuticals, is a potent, nonsteroidal SARM initially investigated for conditions like muscle wasting and osteoporosis. Unlike traditional steroids, it selectively binds to androgen receptors in muscle and bone, offering a targeted approach to enhancing physique and performance.
Discovery and Development
LGD-3303 emerged from Ligand Pharmaceuticals' research pipeline as part of efforts to create tissue-selective androgens. Preclinical studies highlighted its high binding affinity for androgen receptors (AR) and anabolic activity surpassing earlier SARMs like Ostarine (MK-2866). Although Phase I trials demonstrated efficacy in muscle preservation, development stalled, leaving LGD-3303 primarily as a research chemical. Its unapproved status means it's often marketed in fitness circles as a "designer SARM."
Chemical Structure and Pharmacodynamics
LGD-3303's structure features a quinoline core, enhancing AR binding specificity. It exhibits a 10:1 anabolic-to-androgenic ratio in preclinical models, compared to testosterone's 1:1 ratio. This selectivity reduces risks of prostate enlargement or hair loss. Unlike steroids, it does not aromatize into estrogen, mitigating gynecomastia risks.
Mechanism of Action
LGD-3303 activates AR pathways in muscle and bone, stimulating protein synthesis and nitrogen retention. Its selectivity spares organs like the liver and prostate, reducing adverse effects. By bypassing the hypothalamus-pituitary-gonadal (HPG) axis suppression seen with steroids, it offers a safer profile, though mild suppression is still possible at high doses.
Unique Features of LGD-3303
●High Bioavailability: Oral administration with ~90% absorption.
●Long Half-Life: ~24–30 hours, enabling once-daily dosing.
●Nonsteroidal Nature: Avoids hepatotoxicity linked to 17α-alkylated steroids.
●Muscle-Specific Hypertrophy: Promotes lean mass without water retention.
Applications in Bodybuilding
●Bulking Cycles: Enhances lean mass gains (5–10 lbs over 8 weeks).
●Cutting Phases: Preserves muscle during caloric deficits.
●Recomposition: Simultaneous fat loss and muscle growth.
●Injury Recovery: Accelerates repair of connective tissues.
Evidence-Based Benefits
●Muscle Growth: Preclinical data show 6–8% muscle mass increase in 4 weeks.
●Strength Gains: Users report 15–20% boosts in lifts like bench press.
●Fat Oxidation: Upregulates metabolic enzymes, aiding lipolysis.
●Bone Density: Potential use in osteoporosis prevention.
Dosage and Administration
●Beginner: 5–10 mg/day, taken orally with fat for absorption.
●Advanced: 15–20 mg/day (split doses due to long half-life).
●Cycle Length: 8–12 weeks, followed by PCT.
*Note: Human trials used 1–3 mg/day; higher doses are anecdotal.*
Cycle Stacking Strategies
●Mass Building: Stack with MK-677 (Ibutamoren) for IGF-1 synergy.
●Cutting: Combine with Cardarine (GW-501516) for endurance.
●PCT Essentials: Include Nolvadex (20 mg/day) for 4 weeks post-cycle.
Half-Life and Dosing Frequency
With a 24–30-hour half-life, single daily doses suffice. Trough levels remain stable, avoiding peaks linked to side effects.
Post-Cycle Therapy (PCT)
Though milder than steroids, LGD-3303 suppresses natural testosterone. PCT protocols:
●Nolvadex: 20 mg/day (Weeks 1–2), 10 mg/day (Weeks 3–4).
●Enclomiphene: 12.5 mg/day for 4 weeks (more effective for LH/FSH rebound).
Safety and Side Effects
●Common: Mild suppression (30–50% testosterone decline), lethargy.
●Rare: Headaches, lipid profile changes (HDL reduction).
●Mitigation: Liver support (NAC), cholesterol management (omega-3s).
Legal Status
LGD-3303 is not FDA-approved and is prohibited by WADA. Sold as a "research chemical," its legality varies; banned in Australia, unregulated in the U.S. but not for human consumption.
User Experiences
Anecdotal reports highlight rapid strength gains and vascularity, though some note suppressed libido post-cycle. Forums suggest 10 mg/day yields 7–8 lbs of lean mass in 8 weeks.
Clinical Research Insights
A 2010 study in Journal of Pharmacology found LGD-3303 increased lean mass by 9% in orchidectomized rats. Human data remain scarce, emphasizing caution.
Comparison to Other SARMs
Vs. LGD-4033: LGD-3303 has higher AR affinity but shorter development history.
Vs. RAD-140: Less androgenic, making it preferable for cutting.
Ethical Considerations
While SARMs offer a safer alternative to steroids, their unregulated use raises concerns about long-term health impacts and fairness in sports.
Future Prospects
Ongoing research into tissue selectivity may revive LGD-3303 for medical use, such as treating cachexia.
Clinical Data
|
Trade names |
LGD3303 |
|
CAS |
1196133-39-7 |
|
Molar mass |
342.75 |
|
MF |
C16H14ClF3N2O |
|
Purity |
Above 98% |
|
Apprarance |
White Cyrstalline Powder |
Any needs, please contact us
Email: Jasonraws106@gmail.com
WhatsApp: +86-15572565525
Telegram: +86-19128233885
Conclusion
LGD-3303 presents a potent option for bodybuilders seeking muscle growth with fewer side effects. However, its unapproved status and lack of long-term studies necessitate cautious use, emphasizing PCT and health monitoring.
Hot Tags: sarms lgd3303 powder for bodybuilding cas:1196133-39-7, China sarms lgd3303 powder for bodybuilding cas:1196133-39-7 manufacturers, suppliers, factory, AC-262, Andarine S4, YK11, YK11 The strongest SARM for muscle gain, RAD140 increase lean muscle mass, MK2866
